

Volume 17, Number 4

PHREB 17(4) 373-496 (2000)

ISSN 0724-8741

PHARMACEUTICAL RESEARCH

An Official Journal of the American Association of Pharmaceutical Scientists

PHARMACY LIBRARY

JUN 12 2000

2130 CHAMBERLIN HALL
425 N. CHARTER ST. MADISON, WI 53706



Vincent H. L. Lee, Editor-in-Chief, University of Southern California
Daan Crommelin, Editor-Europe, Utrecht University
Mitsuru Hashida, Editor-Japan, Kyoto University
William E. Evans, Associate Editor, St. Jude Children's Research Hospital
Kinam Park, Associate Editor, Purdue University
Melndert Danhof, Associate Editor-Europe, Leiden University
Josef J. Tukker, Associate Editor-Europe, Utrecht University
Randall J. Mersny, Special Features Editor, Genentech

 KLUWER ACADEMIC / PLENUM PUBLISHERS

Encompassing Research
in the Physical,
Chemical, Biological,
Clinical, Socioeconomic,
and Pharmacoeconomic
Aspects of the
Pharmaceutical Sciences

In This Issue:

Bioequivalence
Dissolution Testing
Transdermal Drug Delivery
Pharmaceutical Engineering

DOCKET
ALARM

Find authenticated court documents without watermarks at docketalarm.com.

PHARMACEUTICAL RESEARCH

An Official Journal of the American Association of Pharmaceutical Scientists

Pharmaceutical Research publishes innovative basic research and technological advances in the pharmaceutical-biomedical sciences. Research areas covered in the journal include: pharmaceutics and drug delivery, pharmacokinetics and pharmacodynamics, drug metabolism, pharmacology and toxicology, medicinal chemistry, natural products chemistry, analytical chemistry, chemical kinetics and drug stability, biotechnology, pharmaceutical technology, and clinical investigations, as well as articles on the social, economic, or management aspects of the pharmaceutical sciences.

EDITOR-IN-CHIEF

Vincent H. L. Lee, Department of Pharmaceutical Sciences, University of Southern California, Los Angeles, California

EDITOR—EUROPE

Daan Crommelin, Utrecht University, Utrecht, The Netherlands

EDITOR—JAPAN

Mitsuru Hashida, Kyoto University, Kyoto, Japan

ASSOCIATE EDITORS

William E. Evans, St. Jude Children's Research Hospital, Memphis, Tennessee

Kinam Park, Purdue University, West Lafayette, Indiana

ASSOCIATE EDITORS—EUROPE

Meindert Danhof, Leiden University, Leiden, The Netherlands

Josef J. Tukker, Utrecht University, Utrecht, The Netherlands

EDITOR—SPECIAL FEATURES

Randall J. Mrsny, Genentech, South San Francisco, California

EDITORIAL ADVISORY BOARD

Gordon L. Amidon, University of Michigan, Ann Arbor, Michigan

Per Artursson, Uppsala University, Uppsala, Sweden

Jessie L.-S. Au, Ohio State University, Columbus, Ohio

Clare Bergson, Medical College of Georgia, Augusta, Georgia

Ronald T. Borchardt, University of Kansas, Lawrence, Kansas

Harry Brittain, Center for Pharmaceutical Physics, Milford, New Jersey

John F. Carpenter, University of Colorado, Denver, Colorado

Albert H. L. Chow, Chinese University of Hong Kong, Shatin, Hong Kong

Alice Clark, University of Mississippi, University, Mississippi

Paulo Colombo, University of Parma, Parma, Italy

Michael Corbo, Bristol Meyers Squibb, Hillside, New Jersey

Patrick Couvreur, Université de Paris-Sud, Chateaufort, France

Jennifer B. Dressman, Universität Frankfurt, Frankfurt, Germany

Ronald B. Emeson, Vanderbilt University, Nashville, Tennessee

Ho-Leung Fung, State University of New York-Buffalo, Amherst, New York

Kathleen M. Giacomini, University of California at San Francisco, San Francisco, California

Robert Gurny, Université de Geneve, Geneva, Switzerland

Margareta Hammarlund-Udenaes, Uppsala University, Uppsala, Sweden

Ian Haworth, University of Southern California, Los Angeles, California

Masahiro Hayashi, Science University of Tokyo, Tokyo, Japan

Susan Hershenson, Amgen Inc., Thousand Oaks, California

Tatsuji Iga, University of Tokyo Hospital, Tokyo, Japan

Lisbeth Illum, West Pharmaceutical Service, Nottingham, United Kingdom

Ken-ichi Inui, Kyoto University Hospital, Kyoto, Japan

Myron K. Jacobson, University of Kentucky, Lexington, Kentucky

Rudy L. Juliano, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Hans E. Junginger, University of Leiden, Leiden, The Netherlands

Tetsuya Kamataki, Hokkaido University, Sapporo, Japan

James Kaminski, Schering-Plough Corp., Kenilworth, New Jersey

Neil Kaplowitz, University of Southern California, Los Angeles, California

Chong-Kook Kim, Seoul National University, Seoul, Korea

Kwang-Jin Kim, University of Southern California, Los Angeles, California

Sung Wan Kim, University of Utah, Salt Lake City, Utah

Young Ha Kim, Korea Institute of Science & Engineering, Seoul, Korea

Toshikuro Kimura, Okayama University, Okayama, Japan

Thomas Kissel, Universität Marburg, Marburg, Germany

Joachim Kohn, Rutgers University, Piscataway, New Jersey

Jindrich Kopecek, University of Utah, Salt Lake City, Utah

Richard Lalonde, Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan

Hai Bang Lee, Korea Research Institute of Chemical Technology, Taejeon, Korea

Thomas M. Ludden, GloboMax, Hanover, Maryland

Susan Lunte, University of Kansas, Lawrence, Kansas

Kristina Luthman, Universitetet I Tromso, Tromso, Norway

Panos Macheras, University of Athens, Athens, Greece

Joachim Mayer, University of Lausanne, Lausanne, Switzerland

Duane D. Milles, University of Tennessee, Memphis, Tennessee

Tsuneji Nagai, Hoshi University, Tokyo, Japan

Masahiro Nakano, Kumamoto University Hospital, Kumamoto, Japan

Ralph Niven, Advanced Inhalation Research, Cambridge, Massachusetts

Teruo Okano, Tokyo Women's Medical College, Tokyo, Japan

Charles Pidgeon, Purdue University, West Lafayette, Indiana

Michael J. Pikal, University of Connecticut, Storrs, Connecticut

Ronald E. Reid, University of British Columbia, Vancouver, Canada

Jim E. Riviere, North Carolina State University, Raleigh, North Carolina

Joseph R. Robinson, University of Wisconsin, Madison, Wisconsin

Wolfgang Sadée, University of California, San Francisco, California

Wei-Chiang Shen, University of Southern California, Los Angeles, California

Valentino J. Stella, University of Kansas, Lawrence, Kansas

Yuichi Sugiyama, University of Tokyo, Tokyo, Japan

Sean Sullivan, Valentis, Inc., The Woodlands, Texas

Bonnie L. Svarstad, University of Wisconsin, Madison, Wisconsin

Bernard Testa, University of Lausanne, Lausanne, Switzerland

Kenneth Thummel, University of Washington, Seattle, Washington

Eric Tomlinson, GeneMedicine, Inc., The Woodlands, Texas

Akira Tsuji, Kanazawa University, Kanazawa, Japan

John Urquhart, Palo Alto, California

Arto Urtti, University of Kuopio, Kuopio, Finland

Timothy S. Wiedmann, University of Minnesota, Minneapolis, Minnesota

Keiji Yamamoto, Chiba University, Chiba, Japan

BOOK REVIEW EDITOR

Kinam Park, Purdue University, School of Pharmacy, West Lafayette, Indiana 47097

EDITORIAL ASSISTANTS

Ruth Ellis-Ballard

Elizabeth B. Gongora

Hideo Ueda

Pharmaceutical Research is published monthly by Kluwer Academic/Plenum Publishers, 233 Spring Street, New York, N.Y. 10013-1578. *Pharmaceutical Research* is abstracted or indexed in Bioscience Abstracts, Chemical Abstracts, Current Contents/Life Sciences, Excerpta Medica, Gazette de l'APGI, Index Medicus, International Pharmaceutical Abstracts, Medical Documentation Service/MEDLARS, Reference Update, Science Citation Index, Science Citation Index Expanded, and The ISI Alerting Services. © 2000 Plenum Publishing Corporation. *Pharmaceutical Research* participants in the Copyright Clearance Center (CCC) Transactional Reporting Service. The appearance of a code line at the bottom of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use. However, this consent is given on the condition that the copier pay the flat fee of \$18.00 per copy per article (no additional per-page fees) directly to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, Massachusetts 01923, for all copying not explicitly permitted by Sections 107 or 108 of the U.S. Copyright Law. The CCC is a nonprofit clearinghouse for the payment of photocopying fees by libraries and other users registered with the CCC. Therefore, this consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale, nor to the reprinting of figures, tables, and text excerpts. 0724-8741/00 \$18.00.

Advertising inquiries should be addressed to Advertising Sales, *Pharmaceutical Research*, McNeill Group, Inc., 301 Oxford Valley Road, Suite 903, Yardley, Pennsylvania 19067—telephone (215) 321-9662 and fax (215) 321-9636.

Subscription inquiries and subscription orders should be addressed to the publisher at Subscription Department, Kluwer Academic/Plenum Publishers, 233 Spring Street, New York, N.Y. 10013-1578 or faxed to the Subscription Department at its number (212) 807-1047, or may be telephoned to the Subscription Department's Journal Customer Service at (212) 620-8035, -8404, -8466, -8472, or -8490. Subscription rates:

Volume 17, 2000 (12 issues) \$840.00 (outside the U.S., \$985.00). Prices for individuals subscribers certifying that the journal is for their personal use, \$160.00 (outside the U.S., \$187.00).

Periodicals postage paid at New York, N.Y., and at additional mailing offices. Postmaster: Send address changes to *Pharmaceutical Research*, Kluwer Academic/Plenum Publishers, 233 Spring Street, New York, N.Y. 10013-1578.

Printed in the USA.

What is the True Solubility Advantage for Amorphous Pharmaceuticals?

Bruno C. Hancock^{2,3} and Michael Parks¹

Received September 20, 1999; accepted December 19, 1999

Purpose. To evaluate the magnitude of the solubility advantage for amorphous pharmaceutical materials when compared to their crystalline counterparts.

Methods. The thermal properties of several drugs in their amorphous and crystalline states were determined using differential scanning calorimetry. From these properties the solubility advantage for the amorphous form was predicted as a function of temperature using a simple thermodynamic analysis. These predictions were compared to the results of experimental measurements of the aqueous solubilities of the amorphous and crystalline forms of the drugs at several temperatures.

Results. By treating each amorphous drug as either an equilibrium supercooled liquid or a pseudo-equilibrium glass, the solubility advantage compared to the most stable crystalline form was predicted to be between 10 and 1600 fold. The measured solubility advantage was usually considerably less than this, and for one compound studied in detail its temperature dependence was also less than predicted. It was calculated that even for partially amorphous materials the apparent solubility enhancement (theoretical or measured) is likely to influence *in-vitro* and *in-vivo* dissolution behavior.

Conclusions. Amorphous pharmaceuticals are markedly more soluble than their crystalline counterparts, however, their experimental solubility advantage is typically less than that predicted from simple thermodynamic considerations. This appears to be the result of difficulties in determining the solubility of amorphous materials under true equilibrium conditions. Simple thermodynamic predictions can provide a useful indication of the theoretical maximum solubility advantage for amorphous pharmaceuticals, which directly reflects the driving force for their initial dissolution.

KEY WORDS: amorphous; crystal; solubility; dissolution.

INTRODUCTION

The existence of drugs and excipients in multiple physical forms (*e.g.*, polymorphs, isomers) provides pharmaceutical scientists with an opportunity to select the preferred form(s) of the materials used in a formulation. This is very useful since critical properties, such as particle morphology and solubility, frequently vary between the different physical forms of a material. The amorphous form of pharmacologically active materials has received considerable attention because in theory this form represents the most energetic solid state of a material (Figure 1), and thus it should provide the biggest advantage in terms of solubility and bioavailability (1). Additionally, it may provide significant changes from the usual crystalline form in terms of its mechanical properties, such as elastic modulus.

For different crystalline forms (*e.g.*, polymorphs) the improved solubility of higher energy structures can be reliably estimated from a knowledge of the thermodynamic properties

of the different forms (2). This is most simply achieved when data for the melting point, heat of fusion, and heat capacity of each form are available (*e.g.*, (3)). In many cases it is also possible to directly measure the improvements in solubility and biopharmaceutical performance for such metastable crystal systems (4,5). A consideration of the data in the literature indicates that improvements in solubility resulting from the use of alternate crystal forms can be expected to be as high as two fold (see later for details), and increases in maximum human plasma concentrations of up to six fold may be achieved (4).

The measurement and estimation of the solubility and bioavailability improvements that can be attained by using an amorphous form of a drug presents a more significant challenge because of the far from equilibrium nature of the amorphous state. Thermodynamic predictions of solubility enhancements have not been widely reported because of the difficulties involved in accurately characterizing amorphous drugs in terms of equilibrium thermodynamic properties. Similarly, the determination of meaningful experimental solubilities for amorphous pharmaceutical materials has been found to be extremely difficult because of the tendency for such materials to rapidly revert to the crystalline state upon exposure to small quantities of solvents (*e.g.*, water vapor). Several reports in the literature indicate that the solubility advantage for amorphous drug forms may be quite significant, for example, 1.4 fold for indomethacin (6), 2 fold for cefalexin (7), 2.5 fold for tetracycline (8), and approximately 10 fold for a macrolide antibiotic (9) and novobiocin acid (10). Notably almost all workers cite significant experimental difficulties during solubility measurements due to crystallization of the amorphous drug, and thus their reported experimental solubility ratios are probably underestimates of the true values for these materials. Only a few pharmacokinetic investigations have been reported (in animals) (*e.g.*, (11)), however these indicate that one should expect quite large improvements in the biopharmaceutical performance of amorphous drugs.

In summary, in contrast to polymorphic crystalline drug forms, a simple method to estimate the theoretical maximum solubility of amorphous pharmaceuticals has not yet been proposed, nor has a consistent accurate method for assessing their apparent equilibrium solubilities been reported. Thus, the objective of the work reported herein was to use a simple thermodynamic approach to estimate the theoretical maximum solubility improvement that can be achieved using amorphous compounds and to compare the resulting values with conventionally measured solubility data. It was hoped that this approach would provide an estimate of the increased driving force for the dissolution of amorphous drug forms and indicate its relation to experimentally determined solubility values. To achieve this objective the thermal properties of several drugs were measured using differential scanning calorimetry for use in the solubility calculations. Experimental solubility values were measured directly and/or collated from the literature and then compared to the predicted values.

MATERIALS AND METHODS

Materials

Indomethacin, a hydrophobic poorly water soluble drug, was chosen for detailed characterization and study. Several

¹ Merck Frosst Canada & Co., Kirkland, Quebec, Canada

² Present address: Pfizer Inc., Groton, Connecticut 06340.

³ To whom correspondence should be addressed. (e-mail: bruno_c_hancock@groton.pfizer.com)

other drugs (*i.e.*, glibenclamide, griseofulvin, hydrochlorthiazide, polythiazide) were studied in less detail. All compounds were obtained in their thermodynamically most stable crystalline form from Sigma Chemical Co., St. Louis, MO. The metastable α -polymorph of indomethacin was prepared by precipitation from a saturated methanol solution with water. The amorphous form of each compound was produced by quench cooling molten material in liquid nitrogen. The identity of the different drug forms was established using differential scanning calorimetry and powder X-ray diffraction experiments (see below). All solid samples were stored in a dry environment (over silica gel) and were presented for analysis as powders of less than 120 US mesh size ($\sim 125 \mu\text{m}$).

Thermal Analysis

Powder samples of 5–10 mg were analyzed by differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) using a Seiko-220 thermal analysis system (Haake, Paramus, NJ). Both TGA and DSC experiments were performed in a dry nitrogen atmosphere (60–100 ml/minute), heating the samples at a rate of $10^\circ\text{C}/\text{minute}$ from ambient temperature to above their melting point(s). Calibration of the instruments with respect to temperature and/or enthalpy was achieved using high purity standards of indium, tin and gallium. Sample pans were made of alodined aluminum and were used with a vented cover. The mean results of triplicate determinations are reported.

Powder X-ray Diffraction

Powder x-ray diffraction measurements were used to confirm the crystalline or amorphous nature of the starting materials and to identify the solids remaining in suspension at the end of the solubility experiments. A Scintag XDS-2000 instrument (Scintag, Cupertino, CA) with a nickel filtered copper radiation source was used and scans were taken between 2° and $70^\circ 2\theta$. Samples were presented as lightly compacted powder disks.

Solubility Predictions

Predictions of the relative solubilities of the various crystalline and amorphous forms of each drug were performed according to the method of Parks and co-workers (12,13). In this method the solubility ratio (σ^a/σ^c) of the two forms (amorphous = a; crystalline = c) being examined at any given temperature (T) is considered to be directly related to the free energy difference (ΔG) between those two forms (Fig. 1):

$$\Delta G_{T^a}^c = -R T \ln (\sigma_T^a/\sigma_T^c) \quad (1)$$

where R is the gas constant. The difference in free energy is estimated from the entropy (S) and enthalpy (H) differences between the two forms:

$$\Delta G_{T^a}^c = \Delta H_{T^a}^c - (T \Delta S_{T^a}^c) \quad (2)$$

and these enthalpy and entropy differences are calculated from the melting points (T_f^c), enthalpy and entropy of fusion (ΔH_f^c & ΔS_f^c), and isobaric heat capacities (C_p^c , C_p^a) as follows:

$$\Delta H_{T^a}^c = \Delta H_f^c - (C_p^a - C_p^c)(T_f^c - T) \quad (3)$$

$$\Delta S_{T^a}^c = \Delta S_f^c - (C_p^a - C_p^c)(\ln (T_f^c/T)) \quad (4)$$




Fig. 1. Schematic free-energy diagram for amorphous and crystalline materials (see text for explanation of abbreviations).

$$\Delta S_f^c = \Delta H_f^c/T_f^c \quad (5)$$

This simple approach treats the amorphous form as a pseudo-equilibrium solid state at all temperatures below the melting point, and it is analogous to that which has been successfully used to estimate the relative solubilities of different crystalline polymorphs (2,14). In such instances the heat capacity difference between the two forms (ΔC_p) is usually assumed to be constant, and has often been approximated by $\Delta C_p \approx 0$ or $\Delta C_p \approx \Delta S_f$ when experimental heat capacity data at the temperatures of interest are not available (15–17). In this study actual data for the heat capacity of the amorphous and crystalline forms of indomethacin (18) were used for the calculations, and comparisons were then made with results attained using the commonly applied approximations. Heat capacity differences between the glassy and equilibrium supercooled liquid forms measured at the glass transition (ΔC_{pT_g}) were also available for each of the materials studied and were used for some of the solubility predictions.

Solubility Measurements

Solubility measurements for indomethacin in deionized water were made using a closed, flat-bottomed, water-jacketed, glass vessel (70 mm height \times 70 mm diameter) with an overhead 3-blade propeller stirrer operating at ~ 300 rpm. After equilibration at the desired temperature an excess of powdered drug was placed in the empty vessel, the stirrer started, and then two hundred milliliters of water were added to the vessel. At regular intervals a sample (~ 15 ml) of the liquid phase was withdrawn through a $0.22 \mu\text{m}$ filter and replaced with deionized water of the same temperature. Following dilution with a standard solution of indomethacin in 50:50 methanol/water, the concentration of indomethacin in each sample was determined by UV-visible spectrometry at wavelengths of 266 and 318 nm. Solubility versus time profiles (over a 120 minute period) were determined at least four times for each form of the drug and at three different temperatures (5°C , 25°C , 45°C). The coefficient of variation for replicate determinations was approximately five percent and mean values are reported.

Table 1. Thermal Properties of Different Forms of Indomethacin Measured by Differential Scanning Calorimetry

Form	T _g (°C)	ΔC _{pTg} (J/gK)	T _f (°C)	ΔH _f (J/g)
γ-Crystal	—	—	162	102
α-Crystal	—	—	156	101
Amorphous	42	0.41	—	—

RESULTS

Characterization of Raw Materials

The experimentally determined thermal properties of the different forms of indomethacin are summarized in Table 1, and these results are in close agreement with those previously reported (19,20). The two polymorphic crystal forms differed in their melting point by approximately 6°C and were energetically very similar. The amorphous form was a glass at room temperature and required moderate heating (to above 42°C) to attain the equilibrium supercooled liquid state. The identity of the various indomethacin forms was confirmed using X-ray powder diffraction experiments and comparison to reference data (19). The thermal properties of the other drugs studied were taken from the literature (3–5,12,13, 21) or measured by DSC. These results are presented in the footnote to Table 2.

Solubility Predictions

The predicted solubility ratios for the amorphous and α-crystal forms of indomethacin relative to the γ-crystal form are

summarized in Table 2. A detailed analysis of these predictions will be included in the discussion section. The solubility ratios calculated for the other drugs considered are also summarized in Table 2. The magnitude of the predicted solubility advantage for different crystalline polymorphs ranged from 1.1 to 3.6 fold, whereas the predicted solubility ratio for the amorphous drug forms varied between 12 and 1652 fold.

Solubility Measurements

The experimentally determined solubility versus time profiles for the various indomethacin forms are shown in Figs. 2a, 2b and 2c. At 5°C the enhanced solubility of the amorphous form relative to the γ-crystal is clearly seen. A maximum solubility for the amorphous form occurred at approximately 10 minutes and the solubility of the γ-crystal form reached a constant value at approximately the same time in the experiment. At 25°C the maximum in the solubility versus time profile for the amorphous form was more pronounced. The peak solubility occurred within the first 10 minutes of the experiment and the solubility of the amorphous form was consistently greater than that of the γ-crystal form. At 45°C the peak solubility for the amorphous form occurred very rapidly and declined equally quickly. The α-crystal polymorphic form also had a modestly improved solubility relative to the γ-crystal form at 45°C. The maximum solubility ratios attained at each temperature for the indomethacin forms are summarized in Table 3, along with selected data for other drugs which have been reported in the literature. These literature data were chosen based on their apparent reliability and the possibility of being able to compare them with predicted values (*i.e.*, both thermodynamic and solubility data were available). The experimental

Table 2. Predicted Solubility Ratios for Indomethacin and Other Drug Compounds

Compound	Forms	Solubility ratio ^a	Comment
This work:			
Indomethacin	α-crystal/γ-crystal	1.1 - 1.2	45°C
Indomethacin	amorphous/γ-crystal	38 - 301	5°C
		25 - 104	25°C
		16 - 41	45°C
Literature:			
Carbamezapine (3)	III-crystal/I-crystal	1.7 - 2.1	2°C
		1.7 - 2.0	12°C
		1.6 - 2.0	17°C
		1.6 - 1.9	26°C
		1.6 - 1.8	40°C
		1.5 - 1.7	58°C
Chloramphenicol palmitate (4)	A-crystal/B-crystal	3.6	30°C
Iopanoic acid (21)	II-crystal/I-crystal	2.3 - 2.8	37°C
Mefenamic acid (5)	I-crystal/II-crystal	1.5	30°C
Glibenclamide ^b	amorphous/crystal	112 - 1652	23°C
Glucose (12,13)	amorphous/crystal	16 - 53	20°C
Griseofulvin ^c	amorphous/crystal	38 - 441	21°C
Hydrochlorothiazide ^d	amorphous/crystal	21 - 113	37°C
Iopanoic acid (21)	amorphous/I-crystal	12 - 19	37°C
Polythiazide ^e	amorphous/crystal	48 - 455	37°C

^a The range of values reflects the use of different ΔC_p values for the calculations (see text for details).

^b Glibenclamide: T_g = 58°C, ΔC_{pTg} = 0.45 J/g/K, T_f = 177°C, ΔH_f = 108 J/g.

^c Griseofulvin: T_g = 91°C, ΔC_{pTg} = 0.36 J/g/K, T_f = 221°C, ΔH_f = 107 J/g.

^d Hydrochlorothiazide: T_g = 112°C, ΔC_{pTg} = 0.31 J/g/K, T_f = 274°C, ΔH_f = 104 J/g.

^e Polythiazide: T_g = 73°C, ΔC_{pTg} = 0.34 J/g/K, T_f = 220°C, ΔH_f = 97 J/g.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.